Back to top
more

Amicus Therapeutics (FOLD)

(Delayed Data from NSDQ)

$10.66 USD

10.66
2,750,920

-0.02 (-0.19%)

Updated Apr 15, 2024 04:00 PM ET

After-Market: $10.66 0.00 (0.00%) 7:58 PM ET

Zacks Rank:

This is our short term rating system that serves as a timeliness indicator for stocks over the next 1 to 3 months. How good is it? See rankings and related performance below.

Zacks Rank Definition Annualized Return
1Strong Buy24.15%
2Buy18.00%
3Hold9.44%
4Sell5.10%
5Strong Sell2.53%
S&P50011.08%

Zacks Rank Education - Learn about the Zacks Rank

Zacks Rank Home - Zacks Rank resources in one place

Zacks Premium - The only way to fully access the Zacks Rank

3-Hold of 5     3    

Style Scores:

The Style Scores are a complementary set of indicators to use alongside the Zacks Rank. It allows the user to better focus on the stocks that are the best fit for his or her personal trading style.

The scores are based on the trading styles of Value, Growth, and Momentum. There's also a VGM Score ('V' for Value, 'G' for Growth and 'M' for Momentum), which combines the weighted average of the individual style scores into one score.

Value Score A
Growth Score A
Momentum Score A
VGM Score A

Within each Score, stocks are graded into five groups: A, B, C, D and F. As you might remember from your school days, an A, is better than a B; a B is better than a C; a C is better than a D; and a D is better than an F.

As an investor, you want to buy stocks with the highest probability of success. That means you want to buy stocks with a Zacks Rank #1 or #2, Strong Buy or Buy, which also has a Score of an A or a B in your personal trading style.

Zacks Style Scores Education - Learn more about the Zacks Style Scores

D Value C Growth F Momentum F VGM

Industry Rank:

The Zacks Industry Rank assigns a rating to each of the 265 X (Expanded) Industries based on their average Zacks Rank.

An industry with a larger percentage of Zacks Rank #1's and #2's will have a better average Zacks Rank than one with a larger percentage of Zacks Rank #4's and #5's.

The industry with the best average Zacks Rank would be considered the top industry (1 out of 265), which would place it in the top 1% of Zacks Ranked Industries. The industry with the worst average Zacks Rank (265 out of 265) would place in the bottom 1%.

Zacks Rank Education -- Learn more about the Zacks Rank
Zacks Industry Rank Education -- Learn more about the Zacks Industry Rank

Top 37% (92 out of 252)

Industry: Medical - Biomedical and Genetics

Zacks Premium FeatureView All Zacks #1 Ranked Stocks

Better trading starts here.

Balance Sheet

Research for FOLD

The Zacks Equity Research reports, or ZER for short, are our in-house, independently produced research reports.

The ever popular one-page Snapshot reports are generated for virtually every single Zacks Ranked stock. It's packed with all of the company's key stats and salient decision making information. Including the Zacks Rank, Zacks Industry Rank, Style Scores, the Price, Consensus & Surprise chart, graphical estimate analysis and how a stocks stacks up to its peers.

The detailed multi-page Analyst report does an even deeper dive on the company's vital statistics. In addition to all of the proprietary analysis in the Snapshot, the report also visually displays the four components of the Zacks Rank (Agreement, Magnitude, Upside and Surprise); provides a comprehensive overview of the company business drivers, complete with earnings and sales charts; a recap of their last earnings report; and a bulleted list of reasons to buy or sell the stock. It also includes an industry comparison table to see how your stock compares to its expanded industry, and the S&P 500.

Researching stocks has never been so easy or insightful as with the ZER Analyst and Snapshot reports.

Learn more about Zacks Equity Research reports

See more Zacks Equity Research reports

   

Fiscal Year End for Amicus Therapeutics, Inc falls in the month of December.

All items in Millions except Per Share data.

12/31/2023 12/31/2022 12/31/2021 12/31/2020 12/31/2019
Assets          
Cash & Equivalents 286 294 483 483 453
Receivables 88 66 53 47 33
Notes Receivable 0 0 0 0 0
Inventories 60 24 27 20 14
Other Current Assets 50 40 35 30 20
Total Current Assets 483 424 597 579 520
Net Property & Equipment 32 31 43 44 48
Investments & Advances 0 0 0 0 0
Other Non-Current Assets 0 0 0 0 0
Deferred Charges 0 0 0 0 0
Intangibles 218 198 198 198 198
Deposits & Other Assets 19 42 47 42 51
Total Assets 778 724 905 887 850
Liabilities & Shareholders Equity 12/31/2023 12/31/2022 12/31/2021 12/31/2020 12/31/2019
Notes Payable 0 0 0 0 0
Accounts Payable 15 15 22 17 120
Current Portion Long-Term Debt 0 0 0 0 0
Current Portion Capital Leases 0 0 0 0 0
Accrued Expenses 144 94 98 97 0
Income Taxes Payable 0 0 0 0 0
Other Current Liabilities 0 21 19 9 1
Total Current Liabilities 168 139 146 130 129
Mortgages 0 0 0 0 0
Deferred Taxes/Income 0 10 11 12 14
Convertible Debt 0 0 0 0 2
Long-Term Debt 388 392 389 389 147
Non-Current Capital Leases 0 0 0 0 0
Other Non-Current Liabilities 13 9 8 23 28
Minority Interest (Liabilities) 0 0 0 0 0
Total Liabilities 618 601 598 600 374
Shareholders Equity 12/31/2023 12/31/2022 12/31/2021 12/31/2020 12/31/2019
Preferred Stock 0 0 0 0 0
Common Stock (Par) 3 3 3 3 3
Capital Surplus 2,836 2,665 2,595 2,309 2,227
Retained Earnings -2,684 -2,532 -2,296 -2,045 -1,769
Other Equity 5 -12 5 21 15
Treasury Stock 0 0 0 0 0
Total Shareholder's Equity 160 123 307 286 476
Total Liabilities & Shareholder's Equity 778 724 905 887 850
Total Common Equity 160 123 307 286 476
Shares Outstanding 293.20 280.90 278.60 260.50 254.80
Book Value Per Share 0.55 0.44 1.10 1.10 1.87

Fiscal Year End for Amicus Therapeutics, Inc falls in the month of December.

All items in Millions except Per Share data.

3/31/2024 12/31/2023 9/30/2023 6/30/2023 3/31/2023
Assets          
Cash & Equivalents -99,999 286 280 266 267
Receivables NA 88 73 64 68
Notes Receivable NA 0 0 0 0
Inventories NA 60 57 51 27
Other Current Assets NA 50 53 52 37
Total Current Assets NA 483 463 433 400
Net Property & Equipment NA 32 31 30 31
Investments & Advances NA 0 0 0 0
Other Non-Current Assets NA 0 0 0 0
Deferred Charges NA 0 0 0 0
Intangibles NA 218 219 220 198
Deposits & Other Assets NA 19 21 19 43
Total Assets NA 778 764 730 701
Liabilities & Shareholders Equity 3/31/2024 12/31/2023 9/30/2023 6/30/2023 3/31/2023
Notes Payable NA 0 0 0 0
Accounts Payable NA 15 23 14 25
Current Portion Long-Term Debt NA 0 0 0 0
Current Portion Capital Leases NA 0 0 0 0
Accrued Expenses NA 144 139 125 93
Income Taxes Payable NA 0 0 0 0
Other Current Liabilities NA 0 0 13 13
Total Current Liabilities NA 168 169 159 138
Mortgages NA 0 0 0 0
Deferred Taxes/Income NA 0 6 6 6
Convertible Debt NA 0 0 0 0
Long-Term Debt NA 388 394 393 393
Non-Current Capital Leases NA 0 0 0 0
Other Non-Current Liabilities NA 9 9 10
Minority Interest (Liabilities) NA 0 0 0 0
Total Liabilities NA 618 631 619 598
Shareholders Equity 3/31/2024 12/31/2023 9/30/2023 6/30/2023 3/31/2023
Preferred Stock NA 0 0 0 0
Common Stock (Par) NA 3 3 3 3
Capital Surplus NA 2,836 2,787 2,733 2,692
Retained Earnings NA -2,684 -2,650 -2,629 -2,585
Other Equity NA 5 -7 4 -7
Treasury Stock NA 0 0 0 0
Total Shareholder's Equity NA 160 133 112 103
Total Liabilities & Shareholder's Equity NA 778 764 730 701
Total Common Equity 0 160 133 112 103
Shares Outstanding 295.30 293.20 293.20 284.50 283.30
Book Value Per Share 0.00 0.55 0.45 0.39 0.36